ESMO Breast Cancer 2026, taking place in Berlin in May, will bring several major breast oncology questions into focus: how HER2-positive disease can move toward chemotherapy-sparing strategies, how antibody-drug conjugates may be sequenced after T-DXd, whether ctDNA can help refine early response assessment, and how large-scale genetic testing can shape prevention and long-term care.
This preview highlights 10 presentations to watch across HER2-positive early breast cancer, HER2-positive metastatic breast cancer, ER+/HER2-negative early breast cancer, pan-subtype ADC development, ctDNA-guided treatment strategies, and national germline testing programs. This article is intended as a meeting preview and does not include unpublished results, response rates, survival data, safety outcomes, or slide-level findings.
T-DXd Neoadjuvant Strategies Move Into The Residual Disease Question
LBA1 focuses on residual cancer burden after trastuzumab deruxtecan-based neoadjuvant therapy in HER2-positive early breast cancer, comparing THP versus ddAC-THP strategies after T-DXd exposure.
This question is clinically important because HER2-directed ADCs are increasingly being studied earlier in curative-intent treatment. As T-DXd moves into earlier disease settings, clinicians need clearer evidence on what to do when patients still have residual disease after neoadjuvant ADC-based therapy. The post-neoadjuvant setting is already one of the most important decision points in HER2-positive early breast cancer, and T-DXd introduces a new sequencing question: what should follow when residual cancer burden remains?
LBA1 is therefore important not because it provides answers before the data are presented, but because it addresses a practical clinical scenario that is likely to become more common as ADCs move earlier.
Why It Matters: T-DXd is being studied earlier in HER2-positive early breast cancer, and LBA1 may help frame future decisions for patients with residual disease.
Giredestrant Enters The Early Breast Cancer Conversation
LBA2 brings giredestrant into the early ER+/HER2-negative breast cancer setting through the PREcoppERA/WOO trial. The study evaluates giredestrant versus aromatase inhibitor therapy, with or without LHRHa, in early breast cancer.
The relevance of this abstract goes beyond a single endocrine agent. Oral SERDs have become an important area of research in ER-positive breast cancer, and the early disease setting provides an opportunity to assess biological activity before surgery. Window-of-opportunity studies can help evaluate endocrine response, estrogen receptor pathway suppression, and early tumor biology.
For giredestrant, the key question is whether its biological activity in early ER+/HER2-negative breast cancer supports further development in curative-intent treatment strategies.
Why It Matters: LBA2 may help clarify whether next-generation SERDs can move from metastatic breast cancer research into early breast cancer development.
SATEEN Addresses The Post-T-DXd HER2-Positive Metastatic Gap
LBA4 focuses on one of the most important sequencing questions in HER2-positive metastatic breast cancer: what should come after progression on T-DXd? The SATEEN trial evaluates sacituzumab govitecan plus trastuzumab in patients with HER2-positive metastatic breast cancer after T-DXd progression.
This is a clinically relevant population because T-DXd is increasingly used earlier in HER2-positive metastatic treatment algorithms. As more patients receive T-DXd, post-T-DXd sequencing becomes a growing clinical challenge.
The SATEEN strategy combines continued HER2-directed therapy with trastuzumab and a TROP2-directed ADC, sacituzumab govitecan. Sacituzumab govitecan uses SN-38 as its payload, which differs from the DXd payload used in T-DXd. This makes the study relevant to the broader question of whether a different ADC target and payload strategy can retain activity after prior HER2-directed ADC exposure.
Why It Matters: SATEEN may contribute to evidence generation for treatment selection after T-DXd in HER2-positive metastatic breast cancer.
PHERGain-2 Tests How Far Chemo-Free HER2 De-Escalation Can Go
PHERGain-2 continues one of the most patient-relevant questions in HER2-positive early breast cancer: can selected patients avoid cytotoxic chemotherapy without compromising outcomes? The study evaluates a chemo-free, pCR-guided pertuzumab and trastuzumab strategy in the neoadjuvant setting.
The clinical appeal of this research direction is clear. Reducing chemotherapy exposure could reduce alopecia, neuropathy, fatigue, ovarian toxicity, and long-term treatment burden. However, de-escalation strategies require careful validation, especially in curative-intent disease.
PHERGain-2 is important because it may help refine how response-guided HER2 blockade is evaluated and whether selected patients can be considered for chemotherapy-sparing approaches in future treatment algorithms.
Why It Matters: PHERGain-2 may help define how carefully selected chemo-free HER2-positive early breast cancer strategies should be studied and applied.
Five-Year PHERGain iDFS May Set The De-Escalation Threshold
The 216RO presentation reports 5-year invasive disease-free survival follow-up from the PHERGain trial. Long-term follow-up is particularly important in de-escalation research because early response alone is not enough to support broad changes in curative-intent care.
For HER2-positive early breast cancer, the key issue is durability. A chemotherapy-sparing strategy may be attractive, but it must preserve long-term disease control. Five-year iDFS data can therefore provide a more mature view of whether the response-guided approach remains clinically reassuring over time.
This presentation will be closely followed because it may help determine how the breast oncology community interprets chemo-free de-escalation strategies beyond early endpoints.
Why It Matters: Long-term iDFS follow-up is central to evaluating whether chemo-free HER2 de-escalation can move closer to broader clinical discussion.
TRAIN-4 Adds Tucatinib And ctDNA To The Chemo-Free HER2 Strategy
The 217RO presentation, TRAIN-4, evaluates chemo-free pertuzumab and trastuzumab plus tucatinib in HER2-positive early breast cancer, with ctDNA monitoring included as a translational component.
This trial adds another layer to HER2-positive de-escalation research. Tucatinib is a HER2-selective tyrosine kinase inhibitor, and its integration into a non-cytotoxic antibody backbone raises an important question: can deeper HER2 blockade improve early response while avoiding chemotherapy?
The ctDNA component is also important. If molecular response or ctDNA clearance correlates with pathological response or early treatment sensitivity, ctDNA could become part of future treatment adaptation strategies. For now, this remains an investigational approach, but TRAIN-4 reflects how molecular monitoring is entering neoadjuvant breast cancer research.
Why It Matters: TRAIN-4 connects chemotherapy-sparing HER2 blockade with ctDNA-guided response assessment.
Pyrotinib Plus Pertuzumab Brings Another ctDNA-Guided HER2 Strategy
Abstract 2RO focuses on pyrotinib plus pertuzumab in the neoadjuvant treatment of HER2-positive early breast cancer, with ctDNA monitoring incorporated into the study design. The carousel identifies this as a phase 2 randomized study with a ctDNA endpoint.
This abstract fits into the same broader research theme as TRAIN-4, but with a different HER2-targeted TKI strategy. Pyrotinib is an oral pan-HER tyrosine kinase inhibitor, and combining it with pertuzumab allows investigators to explore another chemotherapy-sparing HER2 blockade approach.
The ctDNA-guided aspect is particularly relevant because breast oncology is increasingly asking whether molecular response can help distinguish patients who may need treatment escalation from those who may be candidates for de-escalation. While pathological complete response remains a key endpoint in neoadjuvant HER2-positive disease, ctDNA may add another layer of biological assessment before surgery.
Why It Matters: Abstract 2RO explores whether ctDNA-guided HER2 blockade can help refine chemotherapy-sparing strategies in HER2-positive early breast cancer.
HER2CLIMB-02 May Clarify The Role Of TKI-ADC Combinations
The 423RO presentation provides an updated overall survival analysis from HER2CLIMB-02, evaluating tucatinib plus T-DM1 versus T-DM1 alone in previously treated HER2-positive metastatic breast cancer.
The update is important because HER2-positive metastatic breast cancer sequencing is changing quickly. T-DXd has reshaped treatment pathways, and later-line regimens must now be interpreted in a more complex ADC-rich landscape.
Tucatinib plus T-DM1 is clinically relevant because it combines a HER2-selective TKI with an antibody-drug conjugate. The updated presentation may help clarify how this type of TKI-ADC combination fits into HER2-positive metastatic disease, especially in treatment sequences where patients have already received multiple HER2-directed therapies.
Why It Matters: HER2CLIMB-02 updated OS data may help inform discussion around TKI-ADC combinations in HER2-positive metastatic breast cancer.
HER3-DXd Tests A Cross-Subtype ADC Strategy
The 422RO presentation focuses on HER3-DXd, patritumab deruxtecan, in metastatic breast cancer across HR+/HER2-negative, HER2-positive, and triple-negative subtypes. The carousel identifies this as a phase 1/2 dose-expansion presentation from the HERTHENA-BC program.
HER3 is an important target of interest because it is expressed across several breast cancer subtypes and is involved in signaling pathways linked to treatment resistance. A HER3-directed ADC may therefore have relevance beyond one traditional breast cancer category.
The key question is whether HER3-DXd can demonstrate meaningful activity and acceptable safety across different breast cancer subtypes, or whether future development will need to focus on more selected populations.
Why It Matters: HER3-DXd may broaden ADC development beyond HER2 and TROP2, with potential relevance across multiple breast cancer subtypes.
UK Genetic Testing Programme Expands The Prevention Conversation
LBA3 shifts the focus from treatment to systems-level cancer care. The UK National Genetic Testing Programme evaluates germline BRCA1/2 testing in patients with a historic diagnosis of breast or ovarian cancer.
This abstract is important because many patients diagnosed years ago did not have access to contemporary germline testing. Identifying pathogenic variants in this population can influence surveillance, risk-reducing surgery, family cascade testing, and prevention strategies for relatives.
The implications go beyond breast oncology clinics. A meaningful testing yield could support broader retrospective testing programs and change how cancer genetics services define eligibility, outreach, and long-term survivorship responsibilities.
Why It Matters: LBA3 may inform national strategies for germline testing in historically treated breast and ovarian cancer populations.
What These Abstracts Say About The Direction Of Breast Oncology
The OncoDaily Breast selection for ESMO Breast Cancer 2026 shows a field moving toward more precise, adaptive, and sequence-aware care. HER2-positive breast cancer dominates the list, reflecting the intensity of current research in ADC sequencing, chemotherapy-sparing strategies, HER2 TKI combinations, and ctDNA-guided response assessment.
At the same time, the program is broader than HER2. Giredestrant brings next-generation endocrine therapy into early ER+/HER2-negative breast cancer. HER3-DXd raises the possibility of a cross-subtype ADC strategy. The UK Genetic Testing Programme highlights the importance of population-level genetics and prevention.
The practical questions are clear: what follows neoadjuvant T-DXd when residual disease remains, how should patients be treated after T-DXd progression, can selected HER2-positive early breast cancer patients safely avoid chemotherapy, can ctDNA help guide early treatment intensity, and should historic cancer populations be brought back into modern germline testing pathways?
For clinicians, ESMO Breast Cancer 2026 is likely to be less about one isolated headline and more about how multiple datasets may shape future discussions around treatment sequencing, de-escalation, molecular monitoring, and long-term care.
Watch full program here